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Consumer medicines information is increasingly relied upon
to inform and empower consumers regarding their medicines.
Legislation and guidelines are now in operation in the US,
European Union (EU) countries and Australasia. The lack of
an evidence base has led to a variety of approaches to written
information provision across the three continents and each
has apparent advantages and disadvantages.  This review
compares consumer medicines information in the three
continents and examines the strengths and weaknesses of
each system. It also includes an outline of research conducted
by Professor Raynor’s team on the impact of the EU
legislation. This will be of particular interest in Malta, in view
of the imminent membership of the EU.
Introduction
Medicines information leaflets are
the bedrock of methods used to inform
people about their medicines.1
Previously the focus was on assisting
people to take or use their medicines
correctly. The focus is now much wider,
as it becomes accepted that people
need to become more involved in
decisions about the medicines that they
take.  Such patient empowerment is at
the heart of a number of policy moves
in the countries of the developed world
e.g. in the UK.2  The notion is that
people not only have a right to full
information about their medicines (to
allow them to make informed decisions
about how and when they take them),
but that adherence with medication will
be enhanced if people take part in such
decisions about their care and
treatments.3
There is a relatively small evidence
base to inform how written medicines
information should be written,
designed and delivered.4 This is
unfortunate, and has meant that recent
legislation, guidelines or targets in:
• Europe,
• US
• Australia & New Zealand
have had relatively limited
underpinning evidence.
The lack of investment in research
into consumer medicines information is
in stark contrast to the amount of
money spent on the discovery,
development and testing of the drugs
themselves.  Paradoxically, the large
amount spent on such developmental
work is largely wasted if patients do
not take their medicines as intended, as
a result of the inadequacy of the
information supplied.
The term Consumer Medicines
Information (CMI) to describe the
patient leaflet supplied with medicines
was first coined in New Zealand and
then adopted by Australia. This review
begins with the story of CMI “down
under”, followed by the US and the
Europe.
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Australasia
In Australia, the Therapeutic Goods
Act requires that CMI is available with
all new medicines.5  It is written by the
manufacturer, and the content needs to
be consistent with the Product
Information (PI) and understandable to
the patient. However, there is no strict
requirement that every piece of
information in the PI must be on the
leaflet. Despite this, some laser-printed
leaflets run to four or five pages.  All
existing medicines are required to have
such a leaflet available by 2003. The
legislation requires that CMI is
available for all prescription
medications, but there is no legal
requirement to provide a CMI with every
supply. Australia adopted a
collaborative approach to the
development of CMI, with a Steering
Committee, a Quality Assurance
Reference Group (QUARG) and
consistency working groups, which
developed core CMI’s for the major drug
groups. The Australian legislation
makes an explicit requirement that the
written information should be
complemented with verbal information.6
Evidence-based guidelines on
writing leaflets were produced by the
Communications Research Institute of
Australia7 and the favoured method of
delivery is computer generation in the
pharmacy (although package inserts
meet the legislative requirements and
are still widely used).  Computer-
generation is the preferred option
because it enables the leaflets to be
kept up-to-date.  There have been a
number of problems in Australia
relating to computer generation in the
pharmacy, due to the cost of buying the
printers and supplying the paper.
However, community pharmacists have
been receiving remuneration for the
delivery of CMI from the end of 2002.
New Zealand is working closely with
Australia on CMI.  The leaflets are not
mandatory in New Zealand and there is
a system of self-assessment by
manufacturers that they need
government guidelines.  Again, the
computer-generated option is preferred.
The content of New Zealand leaflets are
available on www.medsafe.govt.nz/
CMIPage.htm.8
United States
In the United States in the mid
1970’s there was consumer and
professional pressure for legislation
which would require package insert
leaflets for patients. The commercial
sector and some doctors objected and,
as a result, a voluntary system was
introduced.9  These voluntary initiatives
involved leaflets written and produced
by third parties, such as:
• United States Pharmacopeia,
• American Medical Association
• American Society of Health System
Pharmacists.
These are single page leaflets, with
generally more brief information than
contained in the European and
Australian leaflets. The method of
delivery most commonly used is
through computer generation in the
pharmacy.10
The US Government has set targets
for the supply of “useful written
information” to patients when they get
their first supply of medicine. This was
enshrined in Public Law 104-180
(1996), with a first target of 75% by
2000 being achieved. The next target is
95% of patients by 2006.11 In the US
the Food and Drugs Administration
states that written information is at
the core of its efforts to inform
patients.  The same law defines “useful
written information” as being
• scientifically accurate,
• non-promotional,
• specific and comprehensive and
• understandable and legible
As a result of the legislation, a
steering committee was convened in
1996, to facilitate the development of
an “action plan” for evaluating and
improving the usefulness of written
information. The action plan identified
the types of information to be included,
to meet the criteria for being specific
and comprehensive. It also provided
general guidelines for evaluating the
accuracy, legibility and
comprehensibility of written
information.11 An eight-state study in
1999 subsequently evaluated the
written information provided by
community pharmacies. This found that
87% of new prescriptions had some
written information provided (other
than the labels or stickers). Most were
accurate and unbiased and met a
threshold set for information quality.
However, certain categories of
information fell below the threshold
and as a result the authors concluded
that the quality was variable and there
were many areas for improvement.12 In
2001 a further study of written
information provided in community
pharmacies was undertaken.13 A paper
by the same authors used an
instrument based on these criteria to
assess US leaflets by consumer
evaluation of a small subset of
leaflets.14
One exception to the voluntary code
in the United States is covered by
recent legislation for medicines which
the FDA considers “pose serious and
public health concerns”.15  These
medication guides (or Medguides) have
to be produced by the manufacturer and
supplied with every prescription.  They
can be supplied as hard copy or
computer generated and the order and
headings of the leaflet are prescribed.
European Union
In the European Union legislation
was introduced in the 1990’s requiring
a comprehensive medicines information
leaflet for patients, to be supplied
inside the pack of every medicine (EC
Directive 92/27).16  This legislation
came into effect on January 1st 1999
across all member states.
Subsequently, a Guideline on the
readability of the leaflets was
published.17 The leaflets defined by this
legislation have to be written and
supplied by the manufacturer, according
to the detail of the legislation. A key
point is that all information in the
Summary of Product Characteristics (the
PI in the United States) needs to be
provided, but in a form comprehensible
to the patient.  This means that all
warnings, precautions and contra-
indications have to be included.
Before the EU legislation, package
insert leaflets were available in certain
European countries, notably in the
Netherlands, France and Germany.  The
content and distribution method of
these leaflets varied.18 In the United
Kingdom, before the mid-1980’s, few
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leaflets were supplied with medicines.
Then the pharmaceutical industry
sponsored guidelines, based on a two-
sided A5 leaflet, which contained brief
information on one side and more
detailed information on the other.
These were based on research carried
out by Professor Charles George and
colleagues in Southampton.19  However,
in the early 90’s this country-based
initiative was stalled by the publication
of European Union legislation. Current
UK leaflets can be viewed on
www.emc.vhn.net .20
What are the implications
of the EU legislation?
The combination of the large
amount of information to be included
in the leaflets, and the delivery method
as a package insert, results in a small,
thin and folded leaflet that contains a
large amount of information in small
type.  Research in the UK showed that
this method of provision means that
the leaflet is perceived by patients to
be unimportant,21 as the leaflets fall
out of a pack like they do with many
other goods. It is also difficult to
incorporate the leaflets into the wider
information giving process.22 When we
telephoned people seven days after
obtaining a medicine, 83% said they
had noticed the leaflet and 74% had
kept it. However, only 40% said they
had read some and 21% all the
leaflet.21
In another study based on focus
groups of people with asthma, we asked
participants to talk about their
experiences and views of medicines
information. Key points included:
• appearance of the leaflet: “Too
small, folded and in the box”
• Order of information: “Things we
want to know don’t come first”
• Some mistrust of manufacturer’s
leaflet, thought to be written to
protect the manufacturer :”Priorities
are those who wrote it, not
patients”
• Leaflets can only give general
information: “You throw them away
don’t you”, “They don’t inspire you”,
“Never been one for reading the
leaflet all the way through”
• Just giving information is not
enough: “We need to know ‘why’”
• Personal experience was thought to
be more important than drug
company tests “The people using
medicine are best people to know”,
“People who suffer should help
write leaflets”
The EU Readability Guideline 16,
issued in 1999 to complement the
Directive, included sections on:
• Plain Language
• Good design
• Describing risk
• Testing the leaflets
Guidance on good design and the
use of plain language for leaflets in
English are on the website
www.pecmi.org.23 PECMI is ‘Promoting
Excellence in Consumer Medicines
Information’ a UK group of people with
an interest in improving information for
consumers around the supply of
medicines in the UK, both prescription
and self-medication.
In terms of describing risk, the
Guideline suggests terms to describe
risk as follows:
Very common 10%
Common 1-10%
Uncommon 0.1-1%
Rare 0.01-0.1%
Very rare 0.001%- 0.01%
However, our research in more than
1,000 members of public showed that
use of these terms led to gross
overestimation of the risk. For example,
“Very common” is generally interpreted
as being over 50% and “Common”
more than 30%.24,25 More research is
needed to determine the best way of
expressing the risk of side effects to
patients.
An important part of the Guideline
is the recommendation for adopting
“User Testing” (also known as Consumer
or Diagnostic testing to ensure the
effectiveness of the leaflets. This
process assesses if information in
leaflet can be:
• found, and
• understood
Such performance-based testing is
different from content testing; it is
based on how the leaflet performs, not
what it contains.
Typically, 20 consumers in a target
group are questioned on 15 key points
from the leaflet:
• Can they find information in the
leaflet?
• Can they describe it in their own
words?
The aim is for 16 out of 20
consumers to be able to do this. We
carried out some pilot ‘User Testing’ on
3 leaflets, which confirmed that 16/20
is a very hard target to meet.26
What is the way forward?
It is inconceivable that multiply-
folded small print package insert
leaflets, with all their disadvantages,
will continue to be the mainstay of
written consumer medicines
information provision in the 21st
century. Information technologies will
allow computer-generated leaflets to
become the norm (as described above,
they are already the favoured method in
the US and Australia). Computer-
generated leaflets can be:
• Generated at point of supply
• Handed to patient and used as aide
memoire by the pharmacist
• Given only at first supply
• Updated as required
• Personalisation: include patient’s
name
In the future, individualisation of
the information according to the
patient’s age, sex, sight loss, level of
detail, language etc will become
possible. The opportunities for web-
based information extend the options
still further. However, in the short to
medium term, leaflets with medicines
will continue to be the mainstay of
information provided, and further
research is needed to maximise the
benefits for patients.
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